CCL2 is significantly upregulated in primary BrCa, where it is associated with an proinflammatory signature, TAM recruitment, NF-κB activation, poor prognosis, and the risk of early relapse [232,233,234]. Here, CCL2 is linked to invasive breast carcinoma.